CDK4/6 inhibitors are a class of medicines used to ... It appears to affect the CDK4 protein more than the CDK6 protein. Ibrance and Kisqali affect both CDK4 and CDK6 and have to be taken along ...

CDK4/6 inhibitors assist in slowing down cancer growth in women with HR+, HER2- breast cancer. Generally speaking, CDK4/CDK6 ...

Beigene Co. Ltd. has presented data on a CDK4 selective inhibitor, BGB-43395, for the potential treatment of this cancer type and which would reduce the neutropenia associated with CDK6 inhibition.

Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) are the standard first-line treatment for hormone receptor-positive (HR+), human epidermal growth factor receptor ...

There is a huge need to identify patients who may or may not benefit from adding CDK4/6 inhibitors at the time of metastatic diagnosis to guide escalation and de-escalation strategies in advance ...

While the use of CDK4/6 inhibitors combined with endocrine therapy have significantly improved outcomes in patients with HR-positive, HER2-negative metastatic breast cancer, Pedram Razavi ...

Preclinical in vivo studies demonstrated excellent tolerability and single agent efficacy in breast cancer xenograft models with acquired resistance to a CDK4/CDK6 inhibitor - - ETX-197/BG-68501 ...

ETX-197/BG-68501 demonstrated single agent efficacy in a breast cancer xenograft model that had acquired resistance to a CDK4/CDK6 inhibitor. In addition, ETX-197/BG-68501 showed anti-tumor ...

and estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer following CDK4/6 inhibitor (CDK4/6i) therapy. In vivo activity was correlated with E2F1 ...